De novo variants in PAK1 lead to intellectual disability with macrocephaly and seizures.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
01 11 2019
Historique:
received: 02 10 2018
revised: 07 06 2019
accepted: 04 07 2019
pubmed: 11 9 2019
medline: 27 5 2020
entrez: 11 9 2019
Statut: ppublish

Résumé

Using trio exome sequencing, we identified de novo heterozygous missense variants in PAK1 in four unrelated individuals with intellectual disability, macrocephaly and seizures. PAK1 encodes the p21-activated kinase, a major driver of neuronal development in humans and other organisms. In normal neurons, PAK1 dimers reside in a trans-inhibited conformation, where each autoinhibitory domain covers the kinase domain of the other monomer. Upon GTPase binding via CDC42 or RAC1, the PAK1 dimers dissociate and become activated. All identified variants are located within or close to the autoinhibitory switch domain that is necessary for trans-inhibition of resting PAK1 dimers. Protein modelling supports a model of reduced ability of regular autoinhibition, suggesting a gain of function mechanism for the identified missense variants. Alleviated dissociation into monomers, autophosphorylation and activation of PAK1 influences the actin dynamics of neurite outgrowth. Based on our clinical and genetic data, as well as the role of PAK1 in brain development, we suggest that gain of function pathogenic de novo missense variants in PAK1 lead to moderate-to-severe intellectual disability, macrocephaly caused by the presence of megalencephaly and ventriculomegaly, (febrile) seizures and autism-like behaviour.

Identifiants

pubmed: 31504246
pii: 5556429
doi: 10.1093/brain/awz264
pmc: PMC6821231
doi:

Substances chimiques

Actins 0
RAC1 protein, human 0
PAK1 protein, human EC 2.7.11.1
p21-Activated Kinases EC 2.7.11.1
GTP Phosphohydrolases EC 3.6.1.-
CDC42 protein, human EC 3.6.5.2
cdc42 GTP-Binding Protein EC 3.6.5.2
rac1 GTP-Binding Protein EC 3.6.5.2

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3351-3359

Subventions

Organisme : NINDS NIH HHS
ID : K08 NS092898
Pays : United States

Informations de copyright

© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain.

Références

Curr Biol. 1996 May 1;6(5):598-605
pubmed: 8805275
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Mol Biol. 2006 Aug 11;361(2):312-26
pubmed: 16837009
Nucleic Acids Res. 2017 Jan 4;45(D1):D840-D845
pubmed: 27899611
ACS Med Chem Lett. 2015 May 22;6(7):776-81
pubmed: 26191365
Dev Cell. 2007 Nov;13(5):646-62
pubmed: 17981134
Eur J Hum Genet. 2017 Feb;25(2):176-182
pubmed: 27848944
Neuropharmacology. 2009 Jan;56(1):73-80
pubmed: 18644395
Mol Cell. 1998 Jan;1(2):183-92
pubmed: 9659915
Am J Hum Genet. 2018 Feb 1;102(2):309-320
pubmed: 29394990
Neuron. 2002 Jul 3;35(1):121-33
pubmed: 12123613
Am J Hum Genet. 2018 Oct 4;103(4):579-591
pubmed: 30290153
Nature. 2016 Aug 17;536(7616):285-91
pubmed: 27535533
Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11489-94
pubmed: 17592139
Cell. 2000 Aug 4;102(3):387-97
pubmed: 10975528
Res Dev Disabil. 2011 Mar-Apr;32(2):419-36
pubmed: 21236634
Nat Rev Genet. 2016 Jan;17(1):9-18
pubmed: 26503795
Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5861-6
pubmed: 21422296
Am J Hum Genet. 2017 May 4;100(5):695-705
pubmed: 28475856
Mol Cell. 2002 Jan;9(1):73-83
pubmed: 11804587
Mol Cell Biol. 2011 Feb;31(3):388-403
pubmed: 21115725
N Engl J Med. 2012 Nov 15;367(20):1921-9
pubmed: 23033978
Nat Genet. 2014 Mar;46(3):310-5
pubmed: 24487276
Curr Biol. 1997 Mar 1;7(3):202-10
pubmed: 9395435
Cell Logist. 2012 Apr 1;2(2):59-68
pubmed: 23162738
Nat Cell Biol. 1999 Sep;1(5):253-9
pubmed: 10559936
Mol Cell Biol. 2005 May;25(9):3726-36
pubmed: 15831477
J Med Genet. 2015 Dec;52(12):797-803
pubmed: 26424145
Small GTPases. 2014;5:null
pubmed: 24658305
J Mol Biol. 2017 Feb 3;429(3):426-434
pubmed: 27899282
Sci Signal. 2017 Nov 07;10(504):null
pubmed: 29114038

Auteurs

Susanne Horn (S)

Institute of Human Genetics, University Medical Center Leipzig, Leipzig, Germany.

Margaret Au (M)

Department of Pediatrics, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Lina Basel-Salmon (L)

Raphael Recanati Genetic Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel.
Pediatric Genetics Clinic, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel.

Pinar Bayrak-Toydemir (P)

Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA; ARUP Laboratories, Salt Lake City, UT, USA.

Alexander Chapin (A)

ARUP Laboratories, Salt Lake City, UT, USA.

Lior Cohen (L)

Raphael Recanati Genetic Institute, Rabin Medical Center-Beilinson Hospital, Petach Tikva, Israel.
Pediatric Genetics Clinic, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Felsenstein Medical Research Center, Rabin Medical Center, Petach Tikva, Israel.

Mariet W Elting (MW)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Genetics, De Boelelaan 1117, Amsterdam, The Netherlands.

John M Graham (JM)

Department of Pediatrics, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.

Claudia Gonzaga-Jauregui (C)

Regeneron Genetics Center, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.

Osnat Konen (O)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Department of Pediatric Radiology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.

Max Holzer (M)

Department for Molecular and Cellular Mechanisms of Neurodegeneration, Paul Flechsig Institute for Brain Research, University of Leipzig, Leipzig, Germany.

Johannes Lemke (J)

Institute of Human Genetics, University Medical Center Leipzig, Leipzig, Germany.

Christine E Miller (CE)

ARUP Laboratories, Salt Lake City, UT, USA.

Linda K Rey (LK)

Institute of Human Genetics, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.

Nicole I Wolf (NI)

Department of Child Neurology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, and Amsterdam Neuroscience, Amsterdam, The Netherlands.

Marjan M Weiss (MM)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Genetics, De Boelelaan 1117, Amsterdam, The Netherlands.

Quinten Waisfisz (Q)

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Clinical Genetics, De Boelelaan 1117, Amsterdam, The Netherlands.

Ghayda M Mirzaa (GM)

Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Department of Pediatrics, University of Washington, Seattle, Washington, USA.

Dagmar Wieczorek (D)

Institute of Human Genetics, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.

Heinrich Sticht (H)

Institute of Biochemistry, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Rami Abou Jamra (R)

Institute of Human Genetics, University Medical Center Leipzig, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH